Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.



Published on

University of Maryland Baltimore
Experimental Therapeutics Symposium 2009

Published in: Education, Business
  • Be the first to comment


  1. 1. Rena Lapidus PhD Director Translational Lab Shared Service
  2. 2. TLSS Changes <ul><li>Director: Rena Lapidus PhD </li></ul><ul><li>Associate Director: Mariola Sadowska PhD </li></ul><ul><li>Research Assistant: Nidal Muvarak </li></ul><ul><li>TBH – to be hired – in vivo skills as well as bench skills </li></ul>
  3. 3. Rena Lapidus PhD <ul><li>PhD in 1993 from UMD School of Medicine Dept of Pharmacology – Patricia Sokolove PhD </li></ul><ul><li>Post doctoral fellowship at JHU Oncology Center – Nancy Davidson MD </li></ul><ul><ul><li>Epigenetics of breast cancer (estrogen receptor, progesterone receptor) </li></ul></ul><ul><li>12 years industry experience at Guilford Pharmaceutical </li></ul><ul><ul><li>Non-clinical drug development – in vitro and in vivo </li></ul></ul><ul><ul><li>Lead biologist on multi-discipline project teams </li></ul></ul><ul><ul><li>Select projects: </li></ul></ul><ul><ul><ul><li>PARP inhibitor program </li></ul></ul></ul><ul><ul><ul><li>Oral formulation of epigenetic drug, dacogen/decitabine </li></ul></ul></ul><ul><ul><ul><li>Targeting PSMA in prostate cancer </li></ul></ul></ul><ul><ul><ul><li>Chemotherapy induced neuropathy </li></ul></ul></ul>
  4. 4. TLSS Mission <ul><li>Make preclinical in vitro and in vivo model expertise available to on-campus UMGCC members and facilitate the translation of novel therapeutic concepts from bench to bedside </li></ul><ul><li>Add value to advanced preclinical developments of pharmaceutical companies and thus create a pipeline of new drugs for UMGCC clinicians in Phase I and II studies </li></ul><ul><li>Provide UMGCC clinicians with the means to perform early clinical trials of molecularly targeted drugs that require the assessment of pharmacodynamic endpoints </li></ul>
  5. 5. What We Do <ul><li>Support Faculty Members </li></ul><ul><ul><li>Experimentally </li></ul></ul><ul><ul><li>Intellectually </li></ul></ul><ul><ul><li>Experimental design </li></ul></ul><ul><ul><li>Grant writing – sections that are TLSS relevant </li></ul></ul><ul><ul><li>Note: UMGCC faculty members receive a 50% discount – Cancer Ctr subsidizes cost </li></ul></ul>
  6. 6. What can we do - clinicians <ul><li>Support Clinical Trials </li></ul><ul><ul><li>PK – plasma isolation </li></ul></ul><ul><ul><li>Isolate PBMC, bone marrow aspirates </li></ul></ul><ul><ul><li>Process biopsy samples </li></ul></ul><ul><ul><li>PD analysis tailored to specific drug (Western, Elisa, PCR, other specific assays…) </li></ul></ul><ul><li>Develop any novel assay that is requested </li></ul><ul><li>Mariola Sadowska coordinates CT samples – experience handling human samples, PD assay development </li></ul>
  7. 7. What can we do – basic/preclinical <ul><li>Non-clinical – in vitro </li></ul><ul><ul><li>IC50 generation - MTT-like assays </li></ul></ul><ul><ul><li>Flow Cytometry analysis post drug treatment </li></ul></ul><ul><ul><li>Confocal Microscopy/fluorescence microscopy post drug treatment </li></ul></ul><ul><ul><li>PD endpoints </li></ul></ul><ul><li>Non clinical – in vivo </li></ul><ul><ul><li>MTD </li></ul></ul><ul><ul><li>Pharmacokinetic sampling/PD analysis (surrogate tissue/tumor) </li></ul></ul><ul><ul><li>In vivo efficacy – both flank and systemic models </li></ul></ul><ul><li>Human tissue – target validation </li></ul><ul><ul><li>Trained technicians who handle human tissue </li></ul></ul><ul><ul><ul><li>RNA isolation, RT-PCR, Western analysis, Elisa </li></ul></ul></ul><ul><ul><ul><li>Access to clinicians to supply fresh human samples </li></ul></ul></ul>